Shares of Hims & Hers Health surged 9.5% to €26.18 on August 7, extending a sharp rebound that has now clawed back all losses — and then some — from the FTC lawsuit that cratered the stock just nine days ago. The rally matters because it tests whether Wall Street views the federal case as a manageable nuisance or a lasting threat to the telehealth firm's subscription-driven revenue engine.

  • The Government's Case Strikes at the Core Business Model. The FTC, joined by Utah and California, sued Hims & Hers on July 29 alleging the company shared consumers' sensitive health information with advertising platforms like Meta and Snap while deceiving users about billing and cancellation practices.

Regulators also accuse the firm of charging customers for prescriptions before they speak with a provider and making subscriptions difficult to cancel. Those subscriptions are the company's lifeblood — nearly 2.6 million subscribers generated $608 million in Q1 2026 revenue. The company faces potential permanent injunctions, monetary penalties, and heightened regulatory scrutiny that could force costly operational changes to its sign-up and billing flows.

  • The Company Says It's Baseless — But Analysts Are Cutting Targets. Hims & Hers called the lawsuit an attempt to "generate headlines" that "disregards substantial evidence" from a nearly three-year FTC investigation. Yet Bank of America lowered its price target to $30 from $37 the day after the suit dropped. The analyst consensus sits at 6 "Buy" and 13 "Hold" ratings with no "Sell" recommendations — cautious, not panicked.

  • The Rebound Runs Into an Earnings Wall. Shares climbed 23.3% from the lawsuit-day close through August 3 , effectively erasing the damage. But Hims reports Q2 results after the August 10 close , and the numbers are tricky. Q1 gross margin already fell to 65% from 73% a year earlier, and the company swung to a $92.1 million net loss as it shifted from cheaper compounded weight-loss drugs to branded versions from Novo Nordisk and Eli Lilly. Wall Street expects a loss of $0.07 per share for Q2, a 141% year-over-year decline.

  • Trust Is the Real Balance-Sheet Item. Allegations of leaking sensitive medical data could damage the consumer trust that underpins a subscription model where patients share intimate health details. Even if Hims prevails legally, remediation costs and heightened compliance spending could further pressure margins already squeezed by the branded-drug pivot. The stock's recovery reflects optimism; the August 10 earnings call will reveal whether the underlying business supports it.